Lexaria Targets Booming GLP-1 Market With Enhanced Oral Drug Platform

Lexaria Bioscience ( (LEXX) ) has issued an announcement.

Lexaria Bioscience is intensifying its push into the booming GLP-1 drug market with oral capsule and tablet formulations designed to address patient dissatisfaction with injectable therapies and gastrointestinal side effects. Building on formulation advances and new intellectual property secured in 2024 and 2025, the company is enhancing its DehydraTECH GLP-1 platform and has entered early-stage discussions with several multinational pharmaceutical companies that could lead to commercial partnerships.

The company’s strategy is underpinned by strong sector fundamentals, with GLP-1 drugs projected to generate well over $100 billion in annual sales later this decade, led by blockbusters from Eli Lilly and Novo Nordisk. By focusing on better-tolerated oral delivery in a market where many patients discontinue treatment due to discomfort or dislike of injections, Lexaria is positioning itself as a potential partner for major drug makers seeking to retain users and capture long-term growth in obesity and diabetes care.

The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a drug delivery technology company focused on developing improved oral formulations for pharmaceuticals. Its proprietary DehydraTECH platform aims to enhance the tolerability and effectiveness of active ingredients, and the company is currently targeting the rapidly expanding GLP-1 market for diabetes and weight-loss therapies.

Average Trading Volume: 222,601

Technical Sentiment Signal: Strong Sell

Current Market Cap: $18.17M

Learn more about LEXX stock on TipRanks’ Stock Analysis page.